NEW YORK, Jan. 27 (GenomeWeb News) - Led by double-digit revenue growth in its biosciences and medical segments, Becton Dickinson this week reported $1.3 billion in the first quarter, up 9 percent over $1.2 billion in revenues for the year-ago period.
Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.
